New generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment
Peptomyc has raised €17M across 3 funding rounds from 8 investors, most recently a round in Apr 2026. Based in Barcelona, Spain; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-04-09 | Other | €5.0M | Alta Life Sciences,Aurora Science,CDTI Innovación,EIC Fund,Existing investors,Laudecum+1 more | View deal → |
| 2020-12-16 | Other | €11M | Aurora Science | View deal → |
| 2016-05-01 | Seed | €1.0M | Riva y Garcia Private Equity | View deal → |
